Dexcom Stock

Dexcom EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Dexcom (DXCM) as of Jul 23, 2026 is 41.24. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 43.87 — a change of -6.00% (lower).

EV/EBIT

41.24

YoY

-6.00%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Dexcom is 2026 41.24 . EV/EBIT (Enterprise Value to EBIT) of Dexcom was 2025 43.87 . It decreases by -6.00% lower compared to the previous year.

The Dexcom EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
129.09 base
Jan 1, 2020
119.97 base
Jan 1, 2021
195.85 base
Jan 1, 2022
119.50 base
Jan 1, 2023
85.95 base
Jan 1, 2024
49.11 base
Jan 1, 2025 (e)
28.66 base
Jan 1, 2026 (e)
25.58 base
YEARPRICE-TO-EBIT
2026 est 25.58
2025 est 28.66
2024 49.11
2023 85.95
2022 119.50
2021 195.85
2020 119.97
2019 129.09
2018 -56.72
2017 -116.54
2016 -78.11
2015 -114.46
2014 -192.55
2013 -87.12
2012 -16.76
2011 -13.63
2010 -17.14
2009 -7.81
2008 -1.54
2007 -5.36
2006 -5.44
2005 -8.73
Access this data via the Eulerpool API

Dexcom Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Dexcom's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Dexcom's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Dexcom's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Dexcom grows earnings faster than its peers.

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dexcom stock

EV/EBIT (Enterprise Value to EBIT) of Dexcom is 41.24 in 2026.

Access this data via the Eulerpool API

Valuation — Dexcom

All Key Metrics — Dexcom